AUROBINDO

November 8, 2019

| | |
|---|---|
| To<br>Listing Department,<br>**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**<br>Exchange Plaza,<br>Bandra Kurla Complex, Bandra (E),<br>**MUMBAI -400 051**<br><br>**Company Code No. AUROPHARMA** | To<br>The Corporate Relations Department<br>**BSE LIMITED**<br>Phiroz Jeejeebhoy Towers,<br>25th floor, Dalal Street,<br>**MUMBAI -400 001**<br><br>**Company Code No. 524804** |

Dear Sir,

**Sub : Clarification on news article "Aurobindo's buyout of Sandoz assets delayed on FTC query" appeared in ET on November 7, 2019 – Reg.,**

We are pleased to report that we are making good progress in working with the Federal Trade Commission (FTC) as part of the customary merger clearance process. While we cannot comment on the specifics of our ongoing discussions with FTC, we can tell you that the article in The Economic Times, India referenced in FiercePharma's story is factually inaccurate and does not correctly characterize the current status of the approval process. We were disappointed by the reporting in The Economic Times and look forward to sharing a more detailed update at an appropriate time.

Please take the above information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LTD. HYD.